05593676 is referenced by 54 patents and cites 1 patents.

Methods are provided for inducing cell death in B-cells, including neoplastic B-cells, by employing reagents that bind to a B-cell epitope. Particularly, antibodies specific for the marker can be administered to a host to induce death in B-cells to which the antibodies bind or can be used in ex vivo clinical situations to selectively remove B-cells. A B-cell specific oligosaccharide epitope useful as a B-cell marker has been identified. The ligand being recognized on B lymphocytes has no apparent similarities to any of the known pan-B cells markers. In addition, proteins which specifically bind the disclosed epitope are provided. Human monoclonal antibody 216, which recognizes this B-cell epitope, is cytotoxic to B-cells and binds all CD19.sup.+ and CD20.sup.+ B lymphocytes in human peripheral blood and spleen. Furthermore, MAb 216 does not distinguish B cells by the isotype expressed, binding IgG.sup.+ and IgM.sup.+ cells with equal intensity, and also bind all B cells regardless of their CD5 expression. Methods to inhibit neoplastic B-cell growth by administering a B-cell-cytotoxic protein are presented. These products and methods find use in diagnosis and therapy.

Title
Method of killing B cells using antibodies which bind CDIM
Application Number
101436
Publication Number
5593676
Application Date
February 23, 1995
Publication Date
January 14, 1997
Inventor
Nelson N H Teng
Hillsborough
CA, US
Marcia M Bieber
Los Altos
CA, US
Neelima M Bhat
Cupertino
CA, US
Agent
Cooley Godward
Assignee
The Leland Stanford Junior University
CA, US
IPC
C07K 16/28
A61K 39/395
View Original Source